Core Viewpoint - The Trump administration has introduced an executive action to restrict direct-to-consumer advertising for pharmaceuticals, responding to concerns raised by recent developments in the industry [1] Group 1: Executive Action Details - The executive action aims to limit the ability of pharmaceutical companies to advertise directly to consumers, which officials believe could lead to more informed healthcare decisions [1] - This move is part of a broader strategy to address rising drug prices and improve transparency in the pharmaceutical industry [1] Group 2: Industry Impact - The action is expected to have significant implications for companies engaged in direct-to-consumer marketing, particularly those like Hims & Hers Health, which have been prominent in this space [1] - Industry officials are concerned that such restrictions could hinder innovation and access to information for consumers [1]

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi... ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Luminar Technologies, Inc. (NASDAQ: LAZR) between March 20, 2025 and May 14, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline. So what: If you purchased Luminar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

PresentationRoss Cohen So really quickly on disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website. And if you have any questions, please contact your Morgan Stanley sales representative. So thank you all for joining us for the Cartesian fireside chat. I'm really excited to welcome Carsten and Milos Miljkovic, the company's CEO and the CMO. Welcome, Carsten. Welcome, Milos. And I'm Ross Cohen, and I work in the health care investment banking at Morgan Stanley. S ...

Key TakeawaysNew Zealand's annual net immigration surged to 13,066 in July, indicating robust population growth and potential economic expansion.Former President Trump signed a memo requiring pharmaceutical advertisements to disclose all risks, a move poised to significantly impact the drug industry's marketing strategies.The immigration increase could bolster New Zealand's labor market and consumer demand, while the pharma ad mandate is expected to increase compliance costs and potentially reduce advertisi ...

PresentationJames SchneiderSenior Research Analyst Okay. Good afternoon, everybody. Welcome to the Goldman Sachs Communacopia and Technology Conference. My name is James Schneider, I'm the semiconductor analyst here at Goldman Sachs, and it's my pleasure to welcome Cadence and CEO, Anirudh Devgan, with us today. Thanks so much for being here. We appreciate it. ...

PresentationDaniel Cohen Good afternoon. Thanks for joining us. I'm Daniel Cohen. I'm a Managing Director in the -- at Morgan Stanley. I do have to read a disclosure before we start. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we will kick it off. Very honored to have my friend, Paul Josephs, CEO of Lifecore, here with ...

PresentationJames SchneiderSenior Research Analyst Okay. Good afternoon, everybody. Welcome to the Goldman Sachs Communacopia and Technology Conference. My name is James Schneider, I'm the semiconductor analyst here at Goldman Sachs, and it's my pleasure to welcome Cadence and CEO, Anirudh Devgan, with us today. Thanks so much for being here. We appreciate it. ...

BREAKING: Futures Mixed But Oracle Skyrockets On Blowout OutlookKlarna Group (KLAR), a rival of Affirm Holdings (AFRM) in the "buy now, pay later" market, priced its initial public offering above the expected range.The Klarna IPO sold 34.3 million shares at $40 a share vs. the targeted range of $35-$37. The Swedish payments company raised $1.37 billion, giving Klarna an initial valuation of $15.1 billion.KLAR stock will begin trading on the NYSE on Thursday.Klarna argues that it's more of a digital bank tha ...

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...